'Plague - Pipeline Review, H2 2016'; Plague pipeline therapeutics constitutes close to 19 molecules. Out of which approximately 14 molecules are developed by Companies and remaining by the Universities/Institutes.
The report 'Plague - Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development for Plague, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
Plague is an infection caused by the bacterium Yersinia pestis. The organism is transmitted to humans who are bitten by fleas that have fed on infected rodents or by humans handling infected animals. Symptoms include headache, fatigue or malaise, muscle aches, fever and chills, abdominal pain, diarrhea and vomiting, shock and bleeding from mouth, nose or rectum, or under skin. Treatment includes antibiotics.
It also reviews of key players involved in therapeutic development for Plague and features dormant and discontinued projects. Currently, The molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 9, 2 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 3 and 1 molecules, respectively.
Key Topics Covered:
- Plague Overview
- Therapeutics Development
- Pipeline Products for Plague - Overview
- Pipeline Products for Plague - Comparative Analysis
- Plague - Therapeutics under Development by Companies
- Plague - Therapeutics under Investigation by Universities/Institutes
- Plague Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Plague - Products under Development by Companies
- Plague - Products under Investigation by Universities/Institutes
- Plague - Companies Involved in Therapeutics Development
- Aradigm Corporation
- AvidBiotics Corp.
- Endacea, Inc.
- Grifols, S.A.
- iBio, Inc.
- Mucosis B.V.
- Syntiron LLC
- Takeda Pharmaceutical Company Limited
Tetraphase Pharmaceuticals Inc.
For more information about this report visit http://www.researchandmarkets.com/research/sk769k/plague_pipeline